Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Enterprise software vendors (ServiceNow, SAP, Palantir, Zeta, Meta) are racing to launch autonomous-agent platforms. The emphasis is shifting to governance, control and data sovereignty, especially for regulated sectors like banking, as seen in Customers Bank's AI-native banking tie-up with Palantir. Venture investors such as Norwest see opportunity to disrupt finance and ERP incumbents (NetSuite, Sage) through CFO-led buying. Consolidation and talent moves, including Tiny's purchase of Oso Cloud (an authorization vendor serving fintech) and MongoDB's CEO leaving for Meta, signal intensifying competition for the enterprise AI stack.
Mid-October 2026 brought a cluster of CEO and board changes (Fox Factory, Bausch + Lomb, Mattel, Brown-Forman, Odyssey) alongside structural moves such as spin-outs, divestitures, a reverse split and a de-SPAC-style combination (XCF/DevvStream). Companies are using the Q3 earnings window to reset leadership, simplify portfolios and tighten governance. Many of these moves follow weak results (Fox Factory's preliminary Q3 miss) or are driven by activist and shareholder engagement (Stride board additions).
In mid-October 2026, tech executives announced a wave of products that move AI from experimentation to agentic deployment. They span on-device compute (NVIDIA RTX Spark laptops, ASUS, Adobe, Microsoft's 'hybrid intelligence'), enterprise governance (ServiceNow's AI Passport and Control Tower), AI embedded in financial and customer workflows (Intuit, Parloa/TELUS, Brand Concierge), and open data-center hardware (Cisco/NVIDIA 400G optics, Marvell). A countercurrent of safety and ownership concerns runs alongside it: OpenAI's safety-transparency lead resigned, and Mark Chen forecast open-source models with frontier-class capabilities within 6 to 12 months.
In early to mid October 2026, sell-side and independent analysts (Zambonin, Fiorillo, Canady, Zaccardi) turned more bullish on Palantir. They cite customer expansion, net dollar retention, and complementary customer-built AI apps. Palantir also announced a run of ecosystem partnerships in a few days: Customers Bank (AI-native banking), Ondas (Regna AI) and Armada (sovereign AI infrastructure). Over the same period J.P. Morgan's Seth Seifman described weak A&D sentiment, downgraded Leidos and flagged midterm-election and FY2027 budget uncertainty.
Finance chiefs are changing hands (Rivian to GE Vernova, PJT Partners, Penguin Solutions, Fox Factory's interim CEO) while companies run cost programs and restructurings: NIKE's Pace model, Fox Factory's profit optimization, merger synergies at a bank, Marucci divestiture guidance, and debt refinancing. In parallel, AI is moving into the finance function, with PwC and SAP extending their collaboration, SAP showing its Autonomous Enterprise, and Morgan Foods preparing for agentic adoption. Regulation (the Durbin Amendment at Origin Bancorp from mid-2027, FDA PDUFA dates) and a dense run of Q3 earnings and Investor Days add near-term catalysts.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
Data center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedNVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedMortgage Rates Hit 6.33%: Here’s Why Home Affordability Just Jumped 9 Points
“Mortgage Rates Hit 6.33%: Here’s Why Home Affordability Just Jumped 9 Points Quick Read The National Association of Realtors’ Housing Affordability Index surged to 110.6 in April 2026 from 101.4 a year prior, driven by 30-year mortgage rates declining 40 basis points to 6.33% while per capita disposable income rose fro…”
Groupe DÉKUPLE : activité du 1er trimestre 2026
“Groupe DÉKUPLE : activité du 1er trimestre 2026 ACTIVITÉ DU 1ER TRIMESTRE 2026 _____ Chiffre d’affaires : 61,2 M€ (+5,0 %) Revenu net : 45,3 M€ (+2,4 %)Croissance portée par le Marketing Digital (+8,2 %) et l’International (+50,0 %) Paris, le 26 mai 2026 (8h00) - Le Groupe DÉKUPLE, leader européen de la Communication e…”
Exclusive: From Booking Calls To Late Check-Ins, Dextr AI Raises $6.7M For Hotel AI Agents
“Crunchbase News - Funding Ma Title: Exclusive: From Booking Calls To Late Check-Ins, Dextr AI Raises $6.7M For Hotel AI Agents Date: 2026-09-24 13:00 Source: https://news.crunchbase.com/venture/dextr-ai-hospitality-agents-raises-seed-funding/ <p>When <a href="https://www.crunchbase.com/person/sajid-shariff">Sajid Shari…”
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
“Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types Regeneron Pharmaceuticals, Inc…”
Croissance organique de +6,0 % au premier trimestre 2026 - Confirmation des objectifs annuels
“Croissance organique de +6,0 % au premier trimestre 2026 - Confirmation des objectifs annuels Communiqué de presse Roubaix, 8 janvier 2026 Croissance organique de +6,0 % au premier trimestre 2026 Confirmation des objectifs annuels Chiffre d’affaires par segment de produits (en millions d'euros)2025 1er trimestre2026 1e…”
HKIC ends year on high note but Hong Kong cost of living a drawback for attracting talent
“HKIC ends year on high note but Hong Kong cost of living a drawback for attracting talent The success of the government's Hong Kong Investment Corporation (HKIC) in establishing an ecosystem for start-ups to raise funds has put a damper on the Christmas plans for employees of some local venture capital (VC) firms…”
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts measure the same attribute (cash) for the same entity (Tesla Inc.) at the same point in time (2025-12-31). Although labeled with different fiscal period categories (FY 2025 vs Q4 2025), both periods end on the same date, making them equivalent time snapshots. The values differ drastically: $16.513 billion vs $44.06 USD. Since Q4 2025 is the final quarter of FY 2025, both should report identical cash balances at period-end. A 375 million-fold magnitude difference indicates a real contradiction, likely caused by a data quality issue (unit error, miscategorization, or source error in FACT B).
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Every fact is traceable to the document it came from — see how we source every claim.
Analysts turned more bullish on Palantir in mid-October 2026, and the company announced several partnerships. The shares still fell 7% in one session. J.P. Morgan's defense analyst, meanwhile, downgraded Leidos. Every figure here traces to a named source.
SAP and Zeta unveiled autonomous-agent platforms in the same week that Tiny bought an authorization business for about $1.9 million. The details of that sale, and one investor's warning about maths, show where the real work sits. Several sources here have mixed accuracy records, and we flag them.
A Tecentriq approval, a 14 November FDA deadline for Summit's ivonescimab and Novocure's record quarter make this a decisive stretch for cancer medicine. Summit's SEC-verified accounts show how costly the wait has been. The AI claims behind the sector's next leap come from a source our checks rate poorly.
SEC filings show Micron's capital spending rose from $8.4 billion to $15.9 billion in a year, and its cash pile has grown sharply. Alliances, custom chips and optical links are forming around the same memory and data-movement bottleneck. The Wall Street bullishness comes from a source with a weak accuracy record.
Cancer medicine is changing on three fronts at once: next-generation drugs nearing decisions, AI-designed medicines, and a take-private of a care provider. Summit Therapeutics' audited filings show what one pivotal bet has cost: $1.08 billion lost in FY2025 with no revenue.
SEC-filed numbers show Micron nearly doubled its capital spending in fiscal 2025 and now holds about $25 billion in cash. Around it, chipmakers are locking in supply and merging. Several of the sources behind those deals have mixed accuracy records, and we show that below.
A cluster of cancer-drug milestones lands this autumn. One, a Phase 3 myeloma readout, has already reported a 51% cut in progression risk. Two more are dated: ESMO on Oct 24 and an FDA decision on Nov 14. We checked Merck's SEC-filed figures and weighed how reliable each source is.
Two dated events will test oncology's new tools within weeks: Merck and Moderna's personalized mRNA vaccine data at ESMO on Oct. 24, and the FDA decision on Summit's ivonescimab on Nov. 14. We checked Merck's SEC-filed numbers and flag where the sources are weak.
SEC-filed figures show Micron's capital spending roughly doubled in fiscal 2025 and its cash pile has since more than doubled in a year. Analysts back the AI-infrastructure names while flagging a 171x sales multiple at D-Wave and a split consumer. We also show how reliable each source is.
SEC filings show Micron's capital spending nearly doubled in fiscal 2025 and its cash pile has grown to about $25 billion. Analysts expect the AI chip shortage to last 12 to 18 months. We checked the numbers against filings and flagged where the analyst claims rest on weaker sources.
A survey reported by MIT Technology Review finds every respondent plans to use agentic AI within two years, yet AI reaches only part of company data. Money is moving to governance and data plumbing. We checked the figures, and the survey piece itself scores poorly on source reliability.
Several well-known companies announced new chief executives or CEO searches between July and early October 2026. Via News checked each against its source. The handoffs are mostly orderly, but one departure was abrupt, one company is still searching, and the sources' accuracy records vary widely.
Meta's new enterprise platform will be led by MongoDB's departing CEO, while small AI-native startups raise funding. Investors say back-office finance software is next, but one of them warns AI is bad at maths. We flag which sources are weaker and which parts of the story our evidence cannot yet support.
A survey says 100% of organizations plan to use AI agents within two years, yet only about 45% of company data is AI-accessible. We checked the claims against sources, and the survey's publisher scored poorly on reliability, so we flag that. Nvidia's SEC-verified costs show the build-out is real.
A personalised mRNA vaccine from Merck and Moderna stopped melanoma returning in a trial, and AstraZeneca is betting AI can speed up drug design. Via News checked what the record supports: some of the optimism rests on firm data, and some on sources that failed our own reliability tests.
Verified SEC figures show Nvidia's cost of revenue rose about 3.8 times in two fiscal years. A survey says every respondent plans to use AI agents, but company data and trust lag. That survey's source failed our check on all 11 claims we tested, so we flag it and lean on the data that held.
SEC-filed figures show Micron nearly doubled its capital spending in fiscal 2025 and now holds about 2.5 times the cash it had a year earlier. Analyst enthusiasm for power, data-center and quantum stocks rests on sources that held up only about half the time in our checks.
Companies from Manulife to Box customers are rolling out AI agents, and funding is flowing. But a trade-press study reports that in 'data laggard' firms, AI can reach 30% or less of company data. That source has a poor measured record, so we flag it as a claim, not a fact.
Every company surveyed by MIT Technology Review plans to use AI agents within two years, yet firms with weak data give those agents access to 30% or less of it. Only some of this is firmly established: that survey's source scores 0% on our reliability check, and the Nvidia figures are SEC-verified.
Adobe's weak guidance, Alphabet's negative free cash flow, and a wave of safety-driven departures from Anthropic, Google and OpenAI show investors and insiders both demanding proof, not promises — even as California moves first to regulate AI's reach into children's lives.
A single summit produced roughly $950 billion in AI infrastructure deals and locked Nvidia into South Korea's memory supply chain, while one research firm says Wall Street is still underpricing the memory chip boom behind it. Here's what's verified, what's just one analyst's call, and what's still speculative.
C3.ai's CEO sold $4.8 million in stock the same week the industry's biggest AI-agent-trust survey turned out unreliable on 11 checked claims, even as Manulife, Box and a wave of banking and healthcare startups commit real budgets. Via News separates the verified from the unverified.
Google now lets users strip visible watermarks from Gemini-made images, video and music — a move that cuts against the story of an industry rushing toward stronger AI-content labeling, and lands the same week OpenAI lost another senior executive.
Nvidia and South Korea's chipmakers signed roughly $950 billion in new AI agreements in July, including a deal to help secure Nvidia's HBM memory supply from SK Hynix, even as chip stocks logged a sharp correction and the Nasdaq 100 hit a 2.75-month low. Via News traces the deals, earnings and balance-sheet data behind the divergence.
A late-July selloff cut deep into AI-chip stocks — Micron fell nearly 40% from its peak — even as Nvidia expanded its SK hynix memory deal, GlobalFoundries signed a $300M federal photonics award, and Skyworks-Qorvo named a combined leadership team. The data show a maturing boom repricing risk, not a broken one.
Nearly all enterprises surveyed say they'll deploy AI agents within two years, but agents can typically reach under half of company data — and as little as 30% at 'data laggard' firms. Platform giants are selling governance; a new wave of startups is skipping the data problem by targeting narrow, auditable back-office tasks instead.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.